We’ve compiled five essential questions every pet owner should know about the core principles, practical application, side effects, and efficacy of tumor immunotherapy in cats.



| Item | Type | Mechanism of Action | Main Advantage | Precautions |
|---|---|---|---|---|
| Immune Checkpoint Inhibitors | Blocking the PD-1/PD-L1 pathway | Activation of immune cells | Potential for long-term effect | Possibility of immune-related side effects |
| Antibody Therapy | Binding to specific antigens on the cancer cell surface | Direct cell destruction | Precise targeting | High cost, limited response rate |
| Vaccine Therapy | Inducing an immune response via cancer cell antigens | Potential for preventive effect | High safety | Limited therapeutic effect |
Treatment selection is determined by the veterinarian based on the tumor type, condition, and the cat's overall health.

Visit the Clinic Immediately If Abnormal Symptoms Occur During Immunotherapy
If your pet shows signs of fatigue, loss of appetite, vomiting, diarrhea, fever, or skin rashes, it could indicate an excessive immune response or side effects. Please consult your veterinarian immediately.


A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Rassnick KM, Williams LE, Kristal O et al. (2008) Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). Journal of the American Veterinary Medical Association 232, 1200-1205.
[2] Lee, W.S., Yang, H., Chon, H.J. and Kim, C. (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental & Molecular Medicine 52(9), 1475–1485.
[3] Mitchell, L., Thamm, D.H. and Biller, B.J. (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Journal of Veterinary Internal Medicine 26(2), 355–362.